BID polypeptides and methods of inducing apoptosis

• US 7,247,700 B2
• Filed: 12/30/2002
• Issued: 07/24/2007
• Est. Priority Date: 12/31/2001
• Status: Active Grant

• Current Assignee: Dana-Farber Cancer Institute
• Original Assignee: Dana-Farber Cancer Institute
• Inventors: Korsmeyer, Stanley J., Scorrano, Luca
• Primary Examiner(s): Yu; Misook
• Assistant Examiner(s): Halvorson; Mark
• Application Number:
  US10/334,006
• Publication Number:
  US 20030224986A1
• Time in Patent Office: 1,667 Days
• Field of Search: None
• US Class Current: 530/300
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/4747 Apoptosis related proteins

Abstract

Disclosed herein are novel polypeptides and the nucleic acid sequences that encode them. Also disclosed are antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. Vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same are also included. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders involving these novel human nucleic acids and proteins.

Claims

1. An isolated polypeptide which is less than 50 amino acids comprising the amino acid sequence of SEQ ID NO:

2 or 3 wherein said polypeptide does not dimerize with BAX, BCL-2 or BCL-X and wherein said polypeptide remodels the mitochondrial inner membrane.

2. A pharmaceutical composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable carrier.

3. An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:

2.

4. An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:

3.